4.1 Review

Earlier testing for HIV - how do we prevent late presentation?

Journal

ANTIVIRAL THERAPY
Volume 15, Issue -, Pages 17-24

Publisher

INT MEDICAL PRESS LTD
DOI: 10.3851/IMP1526

Keywords

-

Funding

  1. Bristol-Myers Squibb
  2. Abbott Laboratories
  3. Gilead
  4. MSD
  5. GlaxoSmithKline
  6. Pharmacia
  7. Pfizer
  8. Boehringer-Ingelheim
  9. Roche
  10. Schering-Plough
  11. Swedish Orphan
  12. Tibotec

Ask authors/readers for more resources

HIV testing policies and practices vary widely across Europe. It is clear that there are individuals who might present late for HIV diagnosis and care within all risk groups, and potentially in any healthcare setting. This article explores the need to ensure earlier identification and treatment of late-presenting patients by reviewing strategies that might be considered. Such strategies could include routine provider-initiated HIV testing of at-risk groups in settings such as sexually transmitted infection clinics, drug dependency programmes or antenatal care. Healthcare providers might also consider routine HIV testing in all healthcare facilities, in settings including emergency and primary care, where local HIV prevalence is above a threshold that should be further evaluated. They should also take advantage of rapid testing technologies and be aware of barriers to HIV testing among specific groups to provide opportunities for testing that are relevant to local communities.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available